Glioblastoma Hücreleri İçin in Vitro Salinomisin Doz-Cevap Parametreleri R. Seda Tığlı Aydın

Yıl 2016, Cilt: 6 Sayı: 2, 315 - 320, 01.06.2016

R. Seda Tığlı Aydın

Öz

Salinomisin’in SAL kanser tedavisinde teröpatik aktiviteye sahip olduğu daha önceden rapor edilmiştir. Bununla beraber, uygun salinomisin dozlarının glioma hücrelerindeki sitotoksik etkisi halen bilinmemektedir. Bu çalışmada, salinomisin’in in vitro ortamda anti-glioblastoma aktivitesi, doz-cevap verilerinin analizi sonucu elde edilen farmakokinetik/farmakodinamik parametrelerin hesaplanması sonucunda incelenmiştir. 5 µM ve 10 µM dozlarında uygulanan SAL miktarlarının T98G insan glioblastoma hücrelerinde önemli derecede sitotoksik etki gösterdiği tespit edilmiştir. Salinomisin’in doz-cevap parametreleri E0, Einf, IC50, HS, AUC, and GI50 belirlenmiş ve in vitro öncül değerlendirmeler, salinomisin’in T98G glioblastoma hücrelerini hedefleyen anti-kanser ilacı olarak değerlendirilebileceğini ortaya çıkarmıştır

Anahtar Kelimeler

Kanser, Doz-cevap, İlaç, Glioblastoma, Salinomisin

In vitro dose-response parameters of salinomycin for glioblastoma cells

Öz

Salinomycin SAL has been reported previously to exhibit therapeutic activity in cancer. However, appropriate doses of SAL that potentiate cytotoxic effects to glioma cells are still unknown. In this study, in vitro anti-glioblastoma activity of salinomycin with the results of initial set of pharmacokinetics/pharmacodynamics parameters obtained from dose-response data, were evaluated. T98G human glioblastoma cells exposed to 5 µM and 10 µM SAL, showed significant cytotoxicity. Dose-response parameters of salinomycin E0, Einf, IC50, HS, AUC, and GI50 were determined which explores the in vitro preliminary assessment of salinomycin as an anti-cancer drug for targeting T98G glioblastoma cells.

Anahtar Kelimeler

Salinomycin, dose-response, cancer, drug, glioblastoma

Kaynakça

• Al Dhaheri, Y., Attoub, S., Arafat, K., Abuqamars, S., Eid, A., Al Faresi, N., Iratni, R. 2013. Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of surviving and histone H3 and H4 hyperactivation. Biochim. Biophys. Acta. 18(30):312–315.
• Aydın, RST. 2014. Drug targeting systems for cancer therapy: nanotechnological approach. Mini-Rev Med. Chem. 14(13): 1048 – 1054.
• Aydın RST., Kaynak G, Gümüşderelioğlu M. 2016. Salinomycin Encapsulated Nanoparticles As A Targeting Vehicle For Glioblastoma Cells, J. Biomed. Mat. Res. A. 104A(2): 455–464.
• boehmerle, W., Endres, M. 2011. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis. 2: e168.
• Calzolari, A., Saulle, E., De Angelis, M.L., Pasquini, L., boe, A., Pelacchi, F., Ricci-Vitiani, L., baiocchi, M., Testa, U. 2014. Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines. PLoS ONE, 9(4):e94438.
• Delwar, Z.M., Avramidis, D., Siden, A., Cruz, M., Yakisich, S. 2011. Depletion of drug-surviving glioma cells by a second phase treatment with low concentration of salinomycin. Drugs. Ther. Stud., 10:40–45.
• Desouza, M., Gunning, P.W., Stehn, J.R. 2012. The actin cytoskeleton as a sensor and mediator of apoptosis. BioArchitecture 2(3):75–87.
• Fallahi-Sichani, M., Honarnejad, S., Heiser, L.M., Joe, W., Gray, J.W., Sorger, P.K. 2013. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9(11):708–714.
• Gupta, P.b., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., Lander, E.S. 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138: 645-659.
• Harvey, RA. 2008. Drug-receptor interactions pharmacodynamics, In: Clark, M.A., Finkel, R., Rey, J.A., Whalen, K. [eds.] Lippincott’s Illustrated Review: Pharmacology, Lippincott Williams & Wilkins, Baltimore, pp. 30-36.
• Hill, AV. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40:i–vii.